Multiple Myeloma: New Options, New Challenges

Lacy, Martha Q.
July 2006
Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p877
Academic Journal
The article focuses on the development concerning treatment of multiple myeloma. Along with the development is the emergence of new combination regimens in treating the disease. Some of the combination therapies are the pegylated liposomal doxorubicin, vincristine and decreased-frequency dexamethasone with thalidomide. Moreover, these new combination therapies have shown to be effective in treating the disease.


Related Articles

  • Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma. Manochakian, Rami; Miller, Kena C.; Chanan-Khan, Asher Alban // Clinical Cancer Update;Dec2007, Vol. 1 Issue 1, p68 

    Many novel agents and new combinations (including bortezomib, thalidomide, and lenalidomide) have been developed in recent years for the treatment of multiple myeloma (MM), creating major shifts in therapeutic management. Achieving complete response (CR)/near CR (nCR) generally serves as a...

  • The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. R. García-Sanz Jr.; González-Porras; Hernández, J. M.; Polo-zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; López, R.; Grande-García, C.; Alegre, A.; Vargas-Pabón, M.; Gutiérrez, O. N.; Rodríguez, J. A.; Miguel, J. F.San // Leukemia (08876924);Apr2004, Vol. 18 Issue 4, p856 

    We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival. Patients received thalidomide at escalating doses (200-800...

  • A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Chim, C.; Lie, A.; Chan, E.; Leung, Y.; Cheung, S.; Chan, S.; Liang, Raymond; Kwong, Y. // Annals of Hematology;Oct2010, Vol. 89 Issue 10, p1019 

    Bortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (≥75% paraprotein...

  • Long-term outcomes of different bortezomibbased regimens in Chinese myeloma patients. Hua Wang; Liang Wang; Yue Lu; Xiaoqin Chen; Qirong Geng; Weida Wang; Zhongjun Xia // OncoTargets & Therapy;Jan2016, Vol. 9, p587 

    Bortezomib has significantly increased the response rates in multiple myeloma (MM), but optimal bortezomib-based regimens for initial MM therapy have not yet been defined. We retrospectively compared the outcomes of 128 patients newly diagnosed with symptomatic MM who received either bortezomib...

  • High-Dose Glucocorticoid Treatment of Resistant Myeloma. Alexanian, Raymond; Barlogie, Bart; Dixon, Dennis // Annals of Internal Medicine;Jul86, Vol. 105 Issue 1, p8 

    Discusses the effectiveness of intermittent, high-dose dexamethasone treatment given to 49 consecutive patients with refractory multiple myeloma. Response rate of patients to the treatment; Clinical characteristics of patients with resistant or relapsing multiple myeloma; Value of frequent...

  • The Response to Chemotherapy as Prognostic Marker in Multiple Myeloma. Dorina, Petra; Oltean, G.; Smaranda, Demian; Marcela, Candea; Macarie, I. // Acta Medica Marisiensis;2012, Vol. 58 Issue 6, p437 

    Objectives: Even though the correlation between the degree of therapeutic response and overall survival was studied for a long time, there are still contradictory opinions. This study intends to evaluate the prognostic value of response to chemotherapy in terms of patient survival and depending...

  • Antineoplastics/tacrolimus.  // Reactions Weekly;8/2/2008, Issue 1213, p8 

    The article describes the cases of two patients who developed Guillain-Barre syndrome after exposure to high-dose antineoplastics and immunosuppressants associated with peripheral blood stem cell (PBSC) transplantation. The first patient was a man with multiple myeloma who received vincristine,...

  • CLINICAL NEWS.  // British Journal of Hospital Medicine (17508460);Sep2013, Vol. 74 Issue 9, p489 

    This section offers news briefs including MabThera(rituximab) in combination with glococorticoids as the licensed first treatment for granulomatosis with polyangitis, the first-of-a-kind once-daily treatment of Vismodegib has shown to shrink visible lesions in 47% of patients with locally...

  • Régression clinique complète d'une lésion gingivo-mandibulaire de myélome multiple après chimiothérapie exclusive associant dexaméthasone et lénalidomide. A propos d'un cas. Even, Jennifer; LeGoubey, Capucine; Sudrat, Yannick; Devoize, Laurent // Médecine Buccale Chirurgie Buccale;2013, Vol. 19 Issue 2, p113 

    We present the case of a 55 year-old woman with advanced IgA lamba multiple myeloma who developed a mandibular gingival plasmacytoma. Therapeutic solutions are limited, conventional treatments had been all exhausted; it is decided to make an exclusive chemotherapy with a combination of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics